Form 4: Amgen Executive James E. Bradner Reports Stock and Option Awards
SEC Form 4 Filing
James E. Bradner, EVP, R&D, & Chief Sci. Officer of Amgen, reports the acquisition of stock and option awards.
Summary
- On May 7, 2024, James E. Bradner, EVP, R&D, & Chief Sci. Officer of Amgen, reported transactions related to Amgen stock.
- Bradner acquired 2,863 shares of common stock and 18,603 non-qualified stock options (NQSOs).
- The NQSOs have an exercise price of $300.30 and vest in three annual installments starting May 7, 2026.
- The restricted stock units (RSUs) also vest in three annual installments starting May 7, 2026.
- Following the reported transactions, Bradner beneficially owns 25,438 shares of Amgen common stock and 18,603 NQSOs.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which are generally viewed neutrally to positively as they align executive interests with shareholder value. The sentiment is slightly positive due to the incentive structure.
Positives
- The granting of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the granted equity.
Industry Context
Stock and option awards are a common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Equity compensation packages for executives in large-cap biotechnology companies like Amgen typically include a mix of stock options, restricted stock units, and performance-based awards.
- The vesting schedules are generally structured to encourage long-term value creation and retention, often spanning three to five years.
- Compared to companies like Gilead Sciences or Biogen, Amgen's equity grants are within the typical range for executives at similar levels of responsibility.
Stakeholder Impact
- Shareholders: The equity grants align executive interests with shareholder value.
- Employees: The grants are part of the overall compensation structure for executives.
Key Dates
| Date | Description |
|---|---|
| 05/07/2024 | Date of transaction: Grant of stock and options |
| 05/07/2026 | First vesting date for RSUs and NQSOs (33%) |
| 02/09/2026 | First vesting date for some RSUs (2,833 shares) |
| 05/07/2027 | Second vesting date for RSUs and NQSOs (33%) |
| 02/09/2027 | Second vesting date for some RSUs (2,834 shares) |
| 05/07/2028 | Final vesting date for RSUs and NQSOs (34%) |
| 02/09/2028 | Final vesting date for some RSUs (2,920 shares) |
| 05/07/2034 | Expiration date for NQSOs |
| 05/09/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.